4D-150

Drug

Related News

4D-150 Advances in Phase 3 for Wet AMD as 4D Molecular Therapeutics Prepares DME Study

May 17, 2026

4D Molecular Therapeutics said 4D-150 is in Phase 3 for wet AMD and nearing Phase 3 in diabetic macular edema. The company reported rapid enrollment, 18-month treatment burden reductions and favorable safety data.

AAV Gene Therapy Advances for Neovascular AMD and Inherited Retinal Diseases

Feb 13, 2026

AAV-based gene therapy offers sustained intraocular delivery of anti-angiogenic agents with a single treatment for neovascular AMD, with leading clinical candidates including RGX-314, ADVM-022, 4D-150, and NG101.